NCT03632668 is a Phase 1 clinical trial of AD-2071 10/20mg in Hyperlipidemias, sponsored by Addpharma Inc..

Who is sponsoring NCT03632668?

NCT03632668 is sponsored by Addpharma Inc..

What drugs are being tested in NCT03632668?

Interventions in NCT03632668: AD-2071 10/20mg, AD-2072 80/5mg, AD-2071 10/20mg + AD2072 80/5mg.

What condition does NCT03632668 study?

NCT03632668 studies Hyperlipidemias, Hypertension.

Is NCT03632668 still recruiting?

NCT03632668 is currently completed. Last updated 5 July 2019.

Last reviewed 2019-07-05 · How we verify

NCT03632668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Completed Phase 1 Last updated 5 July 2019

What this trial tests

Phase 1 trial testing AD-2071 10/20mg in Hyperlipidemias in 38 participants. Completed in 24 January 2019.

Timeline

28 September 2018

Primary endpoint
24 January 2019

24 January 2019

Quick facts

Lead sponsor	Addpharma Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	28 September 2018
Primary completion	24 January 2019
Estimated completion	24 January 2019
Sites	1 location across South Korea

Drugs / interventions tested

AD-2071 10/20mg — full drug profile →
AD-2072 80/5mg — full drug profile →
AD-2071 10/20mg + AD2072 80/5mg — full drug profile →

Conditions studied

Hyperlipidemias — all drugs for Hyperlipidemias →
Hypertension — all drugs for Hypertension →

Sponsor

Addpharma Inc. — full company profile →

Who can join

Adults 19 to 50, male only, with Hyperlipidemias or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects.
Ryu H, Kim HC, Jeon I, Jang IJ, et al · · 2024 · cited 2× · PMID 38974125 · DOI 10.2147/dddt.s465652

Verify or expand the search:

Other recruiting trials for Hyperlipidemias

Currently open trials in the same condition.

NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting

Other Addpharma Inc. trials

Trials by the same sponsor.

NCT07444385 — A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects · Phase 1 · recruiting
NCT07312799 — Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 · Phase 1 · not yet recruiting
NCT07385235 — Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' · Phase 1 · recruiting
NCT07312773 — A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C · Phase 1 · not yet recruiting
NCT06884085 — A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03632668 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Addpharma Inc.
Last refreshed: 5 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing